Buy, Buy, Buy: Over 40 Companies Acquired in 10 Years! Boston Scientific Corporation Announces Strategic Layout for the Next Decade

According to Mass Device,Boston Scientific's 2023 Investor Day, CEO Mike MahoneyAnnouncing the company's next goal - to make Boston Scientific a "remarkable" and "excellent" place in the next 10 years. The company is currently working throughEnterprise Mergers and Acquisitions, Digitalizationin areas such as... for long-term investment.

"We are elevating our performance," Mahoney said. "We have high expectations for the company, but we want to do the right thing for society while maintaining an excellent corporate culture, and at the same time, aim to provide a unique set of financial reports in the process."

Boston ScientificHas always been the leading enterprise in most fields. In order to strengthen its leading position, it continues to implement a corporate merger and acquisition strategy. Even on the day before the Investor Activity Day, Boston Scientific made a significant merger and acquisition move, announcing that it would...$850 Million Acquisition of Relievant Medsystems。

In the past 12 months, including this agreement, Boston Scientific has completed three acquisitions. At the end of 2022, the company announced plans to acquire for approximately$5.23 billionAcquired for the price ofAcotecThe majority stake. In April this year, the company completed the acquisition ofApollo Endosurgery's $615 Million Acquisition.The multiple acquisitions in the past few years, as well as recent moves, demonstrate Boston Scientific's clear strategy.

"Solidifying the leading position in the track is a key driving factor of this acquisition, and mergers and acquisitions will be an area we continue to focus on."Mahoney said, "It reinforces Boston Scientific's leading position in most fields and helps push it into faster-growing markets.""In the past 10 years, we have acquired more than 40 companies. Although there have been a few failures, most of these small mergers and acquisitions have indeed accelerated our innovation pace and increased our market growth rate."

Boston Scientific also pays great attention to its venture capital portfolio. Mahoney said, "Boston Scientific spends a significant amount of energy on research and development, collaborations, and incubator partnerships worldwide, but we think every day about how to adjust the company's portfolio to make it better."

More Information on the Acquisition

Relievant Medsystems CompanyDeveloped and commercialized the Intracept Intramedullary Nerve Ablation System for chronic pain. This is an FDA-approved minimally invasive procedure for same-day outpatient treatment of chronic vertebrogenic low back pain.

The procedure uses targeted radiofrequency energy to ablate the basivertebral nerve (BVN), stopping the nerve from transmitting pain signals to the brain. The Intracept Basivertebral Nerve Ablation System offers multiple advantages, including being minimally invasive, allowing for same-day surgery, no implants, preservation of the overall spinal structure, and providing long-term pain relief in a single procedure, with the surgery taking only about an hour.

Jim Cassidy, President of Boston Scientific's Neuromodulation Division, spoke about the benefits of acquiring Relievant during the company’s Investor Day: "Vertebral-origin pain represents a significant unmet need, and this acquisition expands Boston Scientific's portfolio in interventional pain management therapies. Our portfolio now includes spinal cord stimulation, traditional radiofrequency, Vertiflex, and Relievant—a combination that is hard to match."

Cast its vision to

Artificial Intelligence and Digitalization

Mahoney stated that Boston Scientific will continue toArtificial Intelligence (AI) and Digital Development. Current imaging, neuromodulation, urologyProducts such as these have already involved artificial intelligence and digitalization, but Boston Scientific's "omni-channel" strategy is not just about integrating AI into the devices themselves—it also aims to enhance business operations through artificial intelligence and digital tools.

"Omni-channel"Is an AI-based sales and marketing platform aimed at consolidating touchpoints from various platforms. Boston Scientific transmits data through an AI interface to deliver the right information and education via the right channel at the right time. This approach accelerates business revenue and provides customers with additional educational opportunities.

In 2021, Boston Scientific also launched an e-commerce platform, which was initially used forEndoscope, and it has currently been expanded toUrologyThe company plans to expand its e-commerce platform to other business segments in 2024, which can effectively save costs and improve efficiency.

In addition, Boston Scientific has an Expert Link tool and technology suite that enables remote services and support. The company developed it during the COVID-19 pandemic, and it is now used for remote patient device calibration, capital equipment maintenance, and physician training.

Boosting Development in the Chinese Market

Mahoney referred to the Chinese market as "one of the most attractive medical technology markets." According to Zhang Jun, President of Greater China at Boston Scientific Corporation, with the increase in demand, particularly inPCI (Percutaneous Coronary Intervention)The growth in procedural surgeries is a particularly attractive point.

The problem at this stage remains how to deal with the complexity in China, including payment reform, local competition, and policy shifts towards local procurement. Nevertheless, Boston Scientific's operations in China are projected to exceed $1 billion in revenue by 2024, with an anticipated growth rate in revenue.

Boston Scientific Seeks to Capture Upside Opportunities While Protecting Downside Risks, Prioritizing Speed, Localization, and Scale. This means accelerating product launches and treatment adoption, maintaining competitiveness through agile and localized operations. At the same time, focusing on highly differentiated product technologies and seeking new growth avenues.

Farapulse and Watchman

At the event day, Boston Scientific not only announced the company's future strategy but also mentioned the recent notable progress of its products Farapulse and Watchman. Farapulse has recently drawn attention due to positive research outcomes, with analysts predicting it will soon receive FDA (U.S. Food and Drug Administration) approval and rapid adoption. Just a week later, the company’s latest left atrial appendage closure (LAAC) device, Watchman FLX Pro, also received FDA approval. Boston Scientific announced that, to date, the number of patients treated with Watchman has exceeded 350,000.

Watchman President Dr. Angelo de Rosa stated: "Today, 38 million people worldwide suffer from atrial fibrillation, and we believe this number will reach 60 million by 2050. We are confident in expanding the indications on a large scale internationally, and the market will exceed $60 billion by 2030."

Regarding Farapulse, Nick Spadea-Anello, President of Electrophysiology, analyzed the market prospects of Boston Scientific. He emphasized the improvement in positive outcomes for patients with Farapulse pulsed field ablation, the simplification of operator procedures, and the significant relief of surgical pressure on hospital systems.

New Advances in Aortic Valve Systems

In addition to the event-related updates, Boston Scientific Corporation also announced the completion of patient enrollment in its Acurate PrimeXL trial, which is primarily aimed at evaluating the Acurate Prime Aortic Valve System. The Acurate Prime Aortic Valve System is an enhancement of the Acurate neo2 Transcatheter Aortic Valve Replacement (TAVR) system, designed to treat severe symptomatic aortic stenosis patients across all risk levels.

Boston Scientific Conducts Research on the Safety and Efficacy of the Acurate Prime Aortic Valve XL (29mm). The study reportedly includes 50 non-randomized subjects across 20 centers in the United States and 1,500 randomized subjects. All subjects who participated in the ACURATE IDE trial have been included in this new research.

In the trial, patients treated with Acurate Prime will be compared with commercially available TAVR systems, such as Edwards Lifesciences' Sapien 3 or CoreValve, CoreValve Evolut, or Medtronic's Evolut Pro system. In the trial, all subjects with implanted devices will be followed up at baseline, perioperative period, and postoperative discharge or seven days after surgery, 30 days, six months, then annually, for up to 10 years post-surgery. Enrolled subjects without implanted devices will be assessed for safety/adverse events within one year after surgery.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Boston Scientific Makes Major Moves in China Production

Just now, the first rotary-type dental implant robot made in China was approved.

The Only "National Heavyweight" Medical Engineering Base in China Breaks Ground

This Giant May Divest Part of Its Diagnostic Imaging Business

Olympus, Major Personnel Changes

SoftBank and Tencent Invest, Surgical Robot Makes Big Moves

Major Executive Changes at the Largest Imaging Service Company in the U.S.

World's First: Chinese-Made Ultrasound to Combat "Female Killer"

Global Dental Giant Acquires Chinese Star Medical Device Company

From 65 Billion to 200 Million, Dental Giant Files for Bankruptcy

BusinessBusiness cooperation email: qxzj@landianyiliao.com